Gravity Analytica

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

ALLO 10.30.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-07

Name of Upcoming Event:Conference Call and Webcast

Full Press Release SEC Filings Our ALLO Tweets

About Gravity Analytica

Recent Filings

01.21.2025 - 144 Report of proposed sale of securities

PDF Version

Conference Call and Webcast Scheduled forNovember 7, 2024at2:00 p.m. PT/5:00 p.m. ET

SOUTH SAN FRANCISCO, Calif.,Oct. 30, 2024(GLOBE NEWSWIRE) --Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR TTM) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update onNovember 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at2:00 p.m. PT/5:00 p.m. ET.

Listen-Only WebcastThe listen-only webcast will be made available on the Company's website atwww.allogene.comunder the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.

Conference Call RegistrationIf you would like the option to ask a question on the conference call, please usethis linkto register. Upon registering for the conference call, you will receive a personal PIN to access the call.

About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T^TM) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visitwww.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for AllogeneThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR TTM is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy OfficerChristine.Cassiano@allogene.com

Source: Allogene Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com